Latest Non-Hodgkin lymphoma Stories
- First and Only Approved Monotherapy in the EU for this Patient Population - BIRMINGHAM, England, April 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc.
Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/
Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc.
MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh,
Scientists say patients with certain forms of aggressive Non-Hodgkin’s Lymphoma are more likely to survive if they respond well to their first treatment. Raleigh,
NIH researchers say risks from occupational exposures such as PCBs cannot be ruled out. Raleigh, NC (PRWEB) March 15, 2014 Researchers with the National
Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh,
- One of a pair of round metal cymbals attached to the fingers and struck together for rhythm and percussion in belly dancing.